L-Isoleucyl-L-arginyl-L-glutaminyl-L-glutaminyl-L-prolyl-L-arginyl-L-?-aspartyl-L-prolyl-L-prolyl-L-threonyl-L-?-glutamyl-L-threonyl-L-leucyl-L-?-glutamyl-L-leucyl-L-?-glutamyl-L-valyl-L-seryl-L-prolyl-L-?-aspartyl-L-prolyl-L-alanyl-L-serine
Ovarian Cancer
Almac Discoveryprotein_peptidePhase 1Dormant
C
36/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 59/ 100
Competitive context
525 Active assets in the Ovarian Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Tisotumab Vedotin Seagen Inc. | Phase 2 | BB |
TIL Inge Marie Svane | Phase 2 | BB |
Olaparib Shandong University | Phase 4 | BB |
Carboplatin Fudan University | Phase 4 | BB |
Irinotecan ARCAGY/ GINECO GROUP | Phase 4 | BB |
View all 50 →
Same molecule, other indications
L-Isoleucyl-L-arginyl-L-glutaminyl-L-glutaminyl-L-prolyl-L-arginyl-L-?-aspartyl-L-prolyl-L-prolyl-L-threonyl-L-?-glutamyl-L-threonyl-L-leucyl-L-?-glutamyl-L-leucyl-L-?-glutamyl-L-valyl-L-seryl-L-prolyl-L-?-aspartyl-L-prolyl-L-alanyl-L-serine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →